Heat-stable egg albumin produced through controlled glycosylation for high-temperature food processing
A clean-label technology that conjugates egg albumin with maltodextrin via controlled Maillard chemistry to prevent heat-induced gelation. Modified egg proteins retain full fluid flowability at 80°C, expanding their use in high-heat processed foods and enabling production of functional protein hydrolysates.
Overview
This technology addresses a key limitation of egg proteins: their tendency to unfold and aggregate into solid gels when exposed to high temperatures. The innovation uses controlled, non-enzymatic glycosylation — an early-stage Maillard reaction — to covalently attach maltodextrin chains to egg albumin. The bulky carbohydrate groups act as a molecular shield, physically blocking unfolded protein chains from self-associating. The result is an egg protein ingredient that withstands severe thermal stress without coagulating, retaining complete fluid flowability even at 80°C.
The approach is clean-label and safe: by carefully controlling the reaction pathway, researchers avoid the advanced browning, nutritional loss, and off-flavors typically associated with Maillard reactions. This unlocks the use of functional egg proteins in high-heat industrial matrices.
Technical specifications
The method couples egg albumin with maltodextrin under controlled reaction conditions. A key innovation is the use of sodium bicarbonate to optimize the reaction — it keeps reactive sites on the protein deprotonated, accelerating the binding process while preserving the non-browning pathway.
Key features:
- Prevents macro-gelation and maintains fluidity under thermal stress up to 80°C
- Clean-label chemistry with no advanced browning, nutritional loss, or off-flavor development
- Tunable process parameters (protein-to-maltodextrin ratio, sodium bicarbonate level, spray-drying conditions) control the degree of glycosylation
- Structural protection verified via FTIR, SDS-PAGE, and spectrophotometric analysis (A420/A600)
- Glycosylated powders can be enzymatically hydrolyzed to generate functional peptides
Technology readiness level
The technology has reached proof-of-concept stage. Preliminary validation demonstrates that modified egg albumin resists coagulation at 80°C while native egg white solidifies under the same conditions. The research team is planning systematic validation across three phases: optimizing reaction kinetics and glycosylation parameters; testing powders in selected food products to confirm solubility, viscosity, and heat stability; and benchmarking glycosylated versus non-glycosylated hydrolysates for solubility, heat stability, and flavor. This work will establish a scalable, food-grade pathway to heat-stable egg proteins and hydrolysates for industrial applications.
About Monash University, Melbourne
Monash University is a comprehensive public research university and one of Australia’s largest, known for scale, interdisciplinarity, and an applied orientation. Its Melbourne-based technology precinct brings together university laboratories, pilot-scale and prototyping suites, and company R&D groups alongside government research organizations to enable co-development and rapid iteration. Integration with a major hospital network supports clinical trials and translation, while structured industry placements and doctoral partnerships create a robust talent pipeline for corporate R&D. Research is backed by competitive funding from the Australian Research Council, the National Health and Medical Research Council, and state and federal programs that incentivize industry collaboration. A dedicated technology transfer office manages IP, licensing, and startup formation, with pathways to incubation and investment within the precinct.
delivered to your inbox.